Long-acting growth hormone dosage forms with superior efficacy to daily somatropin

A long-acting growth hormone or a pharmaceutical formulation comprising such long-acting growth hormone for use in the treatment of growth hormone deficiency, wherein said treatment increases IGF-1 levels in plasma by a standard deviation score of at least 0.2 more than the equivalent dose of daily hGH.

A long-acting growth hormone or a pharmaceutical formulation comprising such long-acting growth hormone for use in a method of increasing the percentage of responders in a patient population suffering from growth hormone deficiency.

A long-acting growth hormone or a pharmaceutical formulation comprising the long-acting growth hormone for use in a method of treating, wherein said long-acting growth hormone or the pharmaceutical formulation is administered in a dose of 0.24 mg/kg/week growth hormone or growth hormone equivalents and administration of said long-acting growth hormone pharmaceutical composition comprising said long-acting growth hormone leads to superior efficacy compared to administration of a dose of 0.24 mg/kg/week of a daily somatropin.